Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy

AI Briefing

• – RV-001 shows promise in treating advanced Retinitis Pigmentosa, with no dose-limiting toxicities reported
• – Interim results from 168-day Phase I/II clinical trial present positive findings for the GPCR-based optogenetic gene therapy
• – RV-001 is set to be further evaluated at upcoming Eyecelerator and Retinal Therapeutics Innovation Summit